课题基金 / 基金详情

Determination of the link between hypertension and Covid-19

Determination of the link between hypertension and Covid-19
确定高血压与 Covid-19 之间的联系
批准号:
62125
负责人:
金额:
$6.04万
依托单位:
依托单位国家:
英国
项目类别:
Feasibility Studies
财政年份:
2020
资助国家:
英国
项目状态:
已结题
起止时间:
2020 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
高血压(未得到控制的高血压)是全球范围内导致过早死亡的主要可预防原因。据估计,全球有13.9亿人患有高血压,2015年约有1070万人死于高血压。预计到2025年,全球将有超过15亿人受到新冠肺炎的影响。在英国,约30%的成年人患有高血压,950万人被诊断出患有高血压,仅在英格兰就可能有500万人尚未意识到高血压。在当前的新冠肺炎大流行中,高血压患者在管理他们的病情方面面临着额外的挑战:\*社会孤立,无法与他们的全科医生/医疗保健专业人员(HCP)见面,\*阅读新闻和科学文献中的报道表明,很高比例的高血压患者感染支付宝后患有严重疾病。通过使用手机应用程序远程监控高血压患者,该应用程序可以记录每日的血压读数、当前的治疗方案并指示任何新冠肺炎症状,从而解决了当前的临床需求,并实现了医疗管理和患者参与,而不需要患者与HCP的直接接触。我们的目标是更新已经开发的针对高血压重点临床研究的手机应用程序,以便在新冠肺炎环境下的新临床试验中部署其他功能。这项试验旨在展示一种“一切照常”的方法来管理和监测长期情况,并收集数据帮助回答高血压社区关心的问题,即:\*使用降压药和/或血压控制水平是否会影响感染新冠肺炎的风险?\*血压药物使用和/或血压控制水平是否会影响新冠肺炎疾病/肺炎的严重程度?\*特定类型的降压药是否会影响新冠肺炎感染的风险?
英文摘要
Hypertension (uncontrolled high blood pressure) is the leading preventable cause of premature death worldwide. Globally, 1.39bn people are estimated to have hypertension, and it caused ~10.7 million deaths in 2015\. It is projected to affect more than 1.5 billion people around the world by 2025\.In the UK ~30% of adults have hypertension, 9.5m have a diagnosis, and a further 5m people in England alone may have hypertension yet be unaware.In the current pandemic of COVID-19, people with hypertension are facing additional challenges in managing their condition as they are:\*socially isolating and not being able to meet with their GP/Healthcare Professional (HCP) with the same frequency\*reading stories in the press and scientific literature that indicate that a high percentage of patients with hypertension who contract COVID-19 have severe illness, are admitted to an intensive care unit, receive mechanical ventilation, or die.Being able to remotely monitor people with hypertension through use of a phone app that records daily BP readings, current treatment regimens and indicate any COVID-19 symptoms will address a current clinical need and enable medical management and patient engagement without the need for direct patient-HCP contact.We aim to update an already developed phone app designed for a hypertension focussed clinical study to include additional features for deployment in a new clinical trial in a COVID-19 setting. The trial will aim to demonstrate a "business as usual" approach to managing and monitoring a long term condition as well as collecting data help to answer questions that are of concern for the hypertension community namely:\*Does blood pressure drug use and/or level of blood pressure control affect risk of COVID-19 infection?\*Does blood pressure drug use and/or level of blood pressure control affect severity of COVID-19 illness/pneumonia?\*Do particular types of blood pressure medication affect risk of COVID-19 infection?
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
LINK-A/miR-155-5p/PKM2轴促进有氧糖酵解介导套细胞淋巴瘤伊布替尼耐药的作用机制研究
  • 批准号:
    LQ21H160036
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    张烨
  • 依托单位:
高性能功率变换器DC-Link电容模组关键技术研究
  • 批准号:
    51777146
  • 项目类别:
    面上项目
  • 资助金额:
    61.0万元
  • 批准年份:
    2017
  • 负责人:
    朱国荣
  • 依托单位:
载CCL5和Link N的HAP水凝胶招募干细胞修复压力诱导的椎间盘退变
  • 批准号:
    81572204
  • 项目类别:
    面上项目
  • 资助金额:
    57.0万元
  • 批准年份:
    2015
  • 负责人:
    熊晓芊
  • 依托单位:
Corey-Link反应的不对称催化研究及其在天然产物合成中的应用
  • 批准号:
    21272221
  • 项目类别:
    面上项目
  • 资助金额:
    80.0万元
  • 批准年份:
    2012
  • 负责人:
    顾振华
  • 依托单位: